Brainstorm Cell Therapeutics Inc (BCLI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) has a cash flow conversion efficiency ratio of -1.341x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($822.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Brainstorm Cell Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Brainstorm Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Brainstorm Cell Therapeutics Inc (BCLI) financial obligations for a breakdown of total debt and financial obligations.
Brainstorm Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainstorm Cell Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FUTURE METALS NL
F:3R10
|
N/A |
|
Anmol India Limited
NSE:ANMOL
|
0.002x |
|
Dr. Martens PLC
LSE:DOCS
|
-0.049x |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
-11.870x |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
0.024x |
|
Koba Resources Ltd
AU:KOB
|
N/A |
|
UNITH LTD.
F:CM30
|
N/A |
|
Clever Group Corp
VN:ADG
|
N/A |
Annual Cash Flow Conversion Efficiency for Brainstorm Cell Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Brainstorm Cell Therapeutics Inc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see Brainstorm Cell Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.76 Million | $-9.09 Million | 1.171x | -72.19% |
| 2023-12-31 | $-4.86 Million | $-20.46 Million | 4.211x | -34.28% |
| 2022-12-31 | $-3.02 Million | $-19.32 Million | 6.408x | +571.89% |
| 2021-12-31 | $19.34 Million | $-26.27 Million | -1.358x | -36.84% |
| 2020-12-31 | $35.46 Million | $-35.19 Million | -0.992x | -207.85% |
| 2019-12-31 | $-12.22 Million | $-11.25 Million | 0.920x | +137.26% |
| 2018-12-31 | $5.02 Million | $-12.39 Million | -2.470x | -514.29% |
| 2017-12-31 | $5.88 Million | $-2.36 Million | -0.402x | +32.04% |
| 2016-12-31 | $9.90 Million | $-5.86 Million | -0.592x | -12.83% |
| 2015-12-31 | $14.13 Million | $-7.41 Million | -0.524x | +22.00% |
| 2014-12-31 | $6.67 Million | $-4.49 Million | -0.672x | +54.58% |
| 2013-12-31 | $2.74 Million | $-4.05 Million | -1.480x | -110.85% |
| 2012-12-31 | $4.15 Million | $-2.92 Million | -0.702x | +53.01% |
| 2011-12-31 | $1.49 Million | $-2.22 Million | -1.494x | -133.14% |
| 2010-12-31 | $-459.00K | $-2.07 Million | 4.508x | +956.02% |
| 2009-12-31 | $-1.74 Million | $-744.00K | 0.427x | -48.90% |
| 2008-12-31 | $-2.08 Million | $-1.73 Million | 0.835x | +14.32% |
| 2007-12-31 | $-2.43 Million | $-1.77 Million | 0.731x | +55.17% |
| 2006-12-31 | $-1.82 Million | $-855.00K | 0.471x | +197.46% |
| 2005-12-31 | $-7.91 Million | $-1.25 Million | 0.158x | +116.45% |
| 2004-12-31 | $704.45K | $-677.84K | -0.962x | -295.97% |
| 2003-12-31 | $-31.44K | $-15.44K | 0.491x | +242.56% |
| 2002-12-31 | $20.36K | $-7.01K | -0.344x | -141.49% |
| 2001-12-31 | $52.16K | $-7.44K | -0.143x | -- |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modula… Read more